Literature DB >> 15709044

Chimeric human immunodeficiency virus type 1 virions that contain the simian immunodeficiency virus nef gene are cyclosporin A resistant.

Mahfuz Khan1, Lingling Jin, Lesa Miles, Vincent C Bond, Michael D Powell.   

Abstract

We have previously shown that human immunodeficiency virus type 1 (HIV-1) virions which have their own nef gene deleted and are trans complemented to contain HIV-2 or simian immunodeficiency virus (SIV) Nef become resistant to treatment with cyclosporin A. To expand and confirm these studies, we have tested an HIV-1 isolate in which the HIV-1 nef gene has been replaced by the nef gene from SIV in a multiround infectivity assay using more physiologically relevant cell types. Our results confirm that HIV-1 virions that contain SIV nef can replicate in a cyclophilin-independent fashion.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15709044      PMCID： PMC548445          DOI： 10.1128/JVI.79.5.3211-3216.2005

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  35 in total

1.  Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.

Authors:  C Aiken
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction.

Authors:  E K Franke; J Luban
Journal:  Virology       Date:  1996-08-01       Impact factor: 3.616

3.  Transfer of the HIV-1 cyclophilin-binding site to simian immunodeficiency virus from Macaca mulatta can confer both cyclosporin sensitivity and cyclosporin dependence.

Authors:  A A Bukovsky; A Weimann; M A Accola; H G Göttlinger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

4.  Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization.

Authors:  J Colgan; H E Yuan; E K Franke; J Luban
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

5.  Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses.

Authors:  D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

6.  The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811.

Authors:  T Dorfman; H G Göttlinger
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

7.  Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis.

Authors:  C Aiken; D Trono
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

8.  Mechanistic independence of Nef and cyclophilin A enhancement of human immunodeficiency virus type 1 infectivity.

Authors:  C Aiken
Journal:  Virology       Date:  1998-08-15       Impact factor: 3.616

9.  Growth properties of HSIVnef: HIV-1 containing the nef gene from pathogenic molecular clone SIVmac239.

Authors:  K Yoon; H W Kestler; S Kim
Journal:  Virus Res       Date:  1998-09       Impact factor: 3.303

10.  Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions.

Authors:  A Billich; F Hammerschmid; P Peichl; R Wenger; G Zenke; V Quesniaux; B Rosenwirth
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103
View more
  2 in total

1.  HIV-1 Nef protein is secreted into vesicles that can fuse with target cells and virions.

Authors:  Tamika D Campbell; Mahfuz Khan; Ming-Bo Huang; Vincent Craig Bond; Michael D Powell
Journal:  Ethn Dis       Date:  2008       Impact factor: 1.847

2.  HIV Type 1 Nef is released from infected cells in CD45(+) microvesicles and is present in the plasma of HIV-infected individuals.

Authors:  A D Raymond; T C Campbell-Sims; M Khan; M Lang; M B Huang; V C Bond; M D Powell
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-21       Impact factor: 2.205
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.